GlassScriptPhysician profile
Sreedevi Daggubati
NPI 1952373656
$5,298.74
in general payments reported to CMS, 2019-2025
41 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,753 · 2020: $477 · 2021: $490 · 2022: $401 · 2023: $162 · 2024: $1,879 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $1,080 · Food and Beverage: $938 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $1,080.33 |
| Food and Beverage | $937.82 |
| Education | $159.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,352.58 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $799.24 | 2019-2025 | Opdivo |
| Janssen Biotech, INC. | $340.12 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $253.69 | 2021-2024 | Precisetumor, Myrisk |
| Genentech USA, INC. | $248.21 | 2019-2024 | Lunsumio, Polivy |
| Rigel Pharmaceuticals, INC. | $183.97 | 2021 | |
| Merck Sharp & Dohme LLC | $177.29 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $176.40 | 2019-2024 | Ultomiris |
| Eisai INC. | $167.80 | 2019 | |
| Pfizer INC. | $165.69 | 2019-2020 | |
| Amgen INC. | $160.87 | 2020-2022 | |
| Genmab U.S., INC. | $124.99 | 2024 | Epkinly |
| Lilly USA, LLC | $124.97 | 2019-2020 | |
| Seagen INC. | $124.67 | 2019-2024 | |
| Agios Pharmaceuticals, INC. | $121.66 | 2020 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $82.22 | 2023-2024 | Libtayo |
| Genzyme Corporation | $70.29 | 2019-2020 | |
| Glaxosmithkline, LLC. | $67.24 | 2021-2022 | |
| Puma Biotechnology, INC. | $58.31 | 2020-2021 | |
| Novocure INC. | $55.55 | 2025 | Optune Lua (Novottf-200t) |
| Celgene Corporation | $55.21 | 2019-2024 | Reblozyl |
| Gilead Sciences, INC. | $42.11 | 2019-2025 | Trodelvy |
| Janssen Pharmaceuticals, INC | $39.10 | 2019 | |
| Emd Serono, INC. | $32.93 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.75 | 2022 | |
| Dendreon Pharmaceuticals LLC | $28.39 | 2019 | |
| Tempus Ai, INC | $27.77 | 2025 | Xt Cdx |
| Array Biopharma INC | $27.65 | 2019 | |
| Dova Pharmaceuticals | $24.45 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.09 | 2019 | |
| Abbvie INC. | $20.86 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.52 | 2020 | |
| Amag Pharmaceuticals, INC. | $16.31 | 2021 | |
| Astellas Pharma US INC | $15.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.47 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.95 | 2019 | |
| Tersera Therapeutics LLC | $12.84 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sreedevi Daggubati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.